Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

New COPD treatment launched

  • Comment

A new treatment for chronic obstructive pulmonary disease has been launched in the UK.

Aclidinium (Eklira Genuair) is a twice daily maintenance bronchodilator treatment to relieve COPD symptoms in adults.

Aclidinium is a long-acting inhaled muscarinic receptor antagonist, while Genuair is a multi-dose dry powder inhaler.

The inhaler has been specially designed to help patients take the medication correctly and prevent accidental double-dosing or using the inhaler when empty, according to its manufacturer Almirall.

The firm said aclidinium had “demonstrated clinically and statistically significant improvements” in lung function, improved disease specific health status, and a reduction in the rate of moderate to severe exacerbations compared to a placebo in trials.

The most frequently reported adverse events in trials with aclidinium were headache and nasopharyngitis.

The product will cost £28.60.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.